CSPC Pharmaceutical Group (01093): Phase III clinical trial of JMT101 combined with osimertinib for first-line treatment of locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion mutations achieves positive topline results

date
18/11/2026
Zhito Finance APP News, CSPC Pharmaceutical Group (01093) announced that the Phase III clinical trial of becotatug (JMT101) developed by the group in combination with osimertinib for first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutation (EGFR ex20ins) has met the primary endpoint in a prespecified interim analysis, achieving positive topline results. Compared with platinum-based chemotherapy combined with pemetrexed, the treatment regimen of this product combined with osimertinib significantly prolonged patients' progression-free survival (PFS) and showed a trend of overall survival (OS) benefit.